Swedish life science company, OnDosis, and global contract development and manufacturing organisation (CDMO), Recipharm, have entered into an agreement for the formulation development of an ADHD treatment for the US market.

The objective is to develop an improved treatment for both the patient and for healthcare professionals. The new treatment for the management of ADHD will be developed by Recipharm’s Centre of Excellence in Oral Solids and will leverage OnDosis’ technology which integrates oral drugs in form of micro pellets and individualised dosing, in a handheld device. The advantages are simplified titration, more accurate dosing and the ability to track dosing and treatment results.

“The global ADHD market amounts to just over 10bn and there is strong demand for new solutions to help better manage this condition that affects a broad patient population. We are very proud to be able to work with OnDosis on such an important project and we believe that our excellent capabilities in drug formulation using coated pellets in Pessac, France, will be very valuable asset throughout the partnership,” said Bernard Pluta, President, Development Services.

“ADHD is a disease area with a significant unmet medical need. It has been confirmed by healthcare professionals that patients with ADHD can experience significant benefits from the new treatment regimen made possible by OnDosis technology. The decision to commence development of a formulation, which will be integrated with OnDosis technology, marks an important milestone for our company and we’re delighted to be working with Recipharm on this critical development work,” said Martin Olovsson, CEO of OnDosis.

Photo of Martin Olovsson